EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Re-administration of platinum-based chemotherapy for recurrent endometrial cancer: an ancillary analysis of the SGSG-012/GOTIC-004/Intergroup study

Shoji Nagao, Shin Nishio, Kazuhiro Takehara, Shinya Sato, Toyomi Satoh, Muneaki Shimada, Satoshi Yamaguchi, Hiroshi Tanabe, Masashi Takano, Kouji Horie, Yuji Takei, Yuichi Imai und 7 weitere

International Journal of Clinical Oncology · 2024-10 · 29 (10) · 1594-1601

DOI: 10.1007/s10147-024-02585-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 13.07.2024. Verfasst von Shoji Nagao und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2…. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Neoplasm Recurrence, Local, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Okayama University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We previously demonstrated the applicability of the concept of “platinum sensitivity” in recurrent endometrial cancer. Although immune checkpoint inhibitors have been widely incorporated into endometrial cancer treatment, the debate continues regarding treatment options in patients with recurrent endometrial cancer who have previously received platinum-based chemotherapy. In this study, we assessed the duration of response to secondary platinum-based treatment using pooled data from the SGSG-012/GOTIC-004/Intergroup study.

Methods

Among the 279 participants in the SGSG-012/GOTIC-004/Intergroup study wherein platinum-based chemotherapy was re-administered for managing recurrent endometrial cancer between January 2005 and December 2009, 130 (47%) responded to chemotherapy. We compared the relationship between platinum-free interval and duration of secondary platinum-based treatment using pooled data.

Results

In 40 patients (31%), the duration of response to secondary platinum-based treatment exceeded the platinum-free interval. The duration of response to secondary platinum-based treatment exceeded 12 months in 51 patients (39%) [platinum-free interval: < 12 months, 14/48 (29%); 12–23 months, 18/43 (42%); 24–35 months, 8/19 (42%); ≥ 36 months, 11/20 (55%)]. In particular, in eight patients (6%), the duration of response to secondary platinum-based treatment exceeded 36 months [platinum-free interval: < 12 months, 3/48 (6%); 12–23 months, 0/19 (0%); 24–35 months, 2/19 (11%); ≥ 36 months, 3/20 (15%)].

Conclusions

Re-administration of platinum-based chemotherapy for recurrent endometrial cancer may result in a long-term response exceeding the platinum-free interval in some patients. Even in the current situation, where immune checkpoint inhibitors have been introduced, re-administration of platinum-based chemotherapy is worth considering.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsNeoplasm Recurrence, LocalAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMiddle AgedAgedAdultCisplatin

Stichwörter der Autor:innen

Platinum-free intervalRe-administration of platinum-based chemotherapyRecurrent endometrial cancerSecondary platinum response

Substanzen

Cisplatin

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan. s_nagao@okayama-u…
  • Department of Obstetrics and Gynecology, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Japan.
  • Department of Gynecologic Oncology, NHO Shikoku Cancer Center, 160 Minami Umenomoto, Matsuyama, Japan.
  • Department of Obstetrics and Gynecology, Tottori University, 36-1 Nishi-cho, Yonago, Japan.
  • Department of Obstetrics and Gynecology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Japan.
  • Department of Gynecology, Tohoku University Hospital, 1-1 Seiryo-machi, Aoba-ku, Sendai, Japan.

Förderung

  • Okayama University

Zitieren

APA

Nagao, S., Nishio, S., Takehara, K., Sato, S., Satoh, T., Shimada, M., Yamaguchi, S., Tanabe, H., Takano, M., Horie, K., Takei, Y., Imai, Y., Hibino, Y., Hasegawa, K., Takekuma, M., Nakamura, K., Takano, H., Fujiwara, K., & Masuyama, H. (2024). Re-administration of platinum-based chemotherapy for recurrent endometrial cancer: an ancillary analysis of the SGSG-012/GOTIC-004/Intergroup study. International Journal of Clinical Oncology, 29(10), 1594-1601. https://doi.org/10.1007/s10147-024-02585-1

Vancouver

Nagao S, Nishio S, Takehara K, Sato S, Satoh T, Shimada M, et al. Re-administration of platinum-based chemotherapy for recurrent endometrial cancer: an ancillary analysis of the SGSG-012/GOTIC-004/Intergroup study. International Journal of Clinical Oncology. 2024;29(10):1594-1601. doi:10.1007/s10147-024-02585-1

BibTeX
@article{Nagao2024,
  author = {Nagao, Shoji and Nishio, Shin and Takehara, Kazuhiro and Sato, Shinya and Satoh, Toyomi and Shimada, Muneaki and Yamaguchi, Satoshi and Tanabe, Hiroshi and Takano, Masashi and Horie, Kouji and Takei, Yuji and Imai, Yuichi and Hibino, Yumi and Hasegawa, Kosei and Takekuma, Munetaka and Nakamura, Kazuto and Takano, Hirokuni and Fujiwara, Keiichi and Masuyama, Hisashi},
  title = {Re-administration of platinum-based chemotherapy for recurrent endometrial cancer: an ancillary analysis of the SGSG-012/GOTIC-004/Intergroup study},
  journal = {International Journal of Clinical Oncology},
  year = {2024},
  volume = {29},
  number = {10},
  pages = {1594--1601},
  doi = {10.1007/s10147-024-02585-1}
}
Kostenlos starten →